Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2022-12-01
Цуврал:	Frontiers in Medicine
Нөхцлүүд:	actinium-225 neuroendocrine tumor peptide receptor radionuclide therapy (PRRT) targeted α-particle therapy SSTR SSTR antagonist
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1034315/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!